Brief: Baudax Bio Q2 EPS continuing operations USD -1.49
16/08/2023 13:24
Aug 16 (Reuters) - Baudax Bio, Inc. Q2 net income continuing operations USD -7.301 million. * Q2 basic EPS USD -1.51 * Q2 EPS continuing operations USD -1.49 * Q2 operating expenses USD 7.045 million * Q2 operating income from continuing operations USD -7.045 million
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer